Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Hepatitis C, Chronic; Hepatitis C

Treatments: Biological: PegIntron (peginterferon alfa-2b; SCH 54031) pen; Drug: Rebetol (ribavirin; SCH 18908)

Study type: Observational

Funder types: Industry

Identifiers

NCT00704717

P04301

Details and patient eligibility

About

The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed regimen which, in turn, is affected by the ease of use and accuracy of treatment administration. Since the PegIntron pen is a novel device, the results of this study will be used to improve the training of patients and healthcare providers in PegIntron pen use.

Enrollment: 185 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hepatitis C under treatment with PegIntron Pen and Rebetol in Romania.

Exclusion criteria

• Not applicable

Trial design

185 participants in 1 patient group

All Treated Patients

Description:

All patients participating in the study.

Treatment:

Drug: Rebetol (ribavirin; SCH 18908)

Biological: PegIntron (peginterferon alfa-2b; SCH 54031) pen